HPV16 E7 TCR Citations (2)

Originally described in: Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.
Jin BY, Campbell TE, Draper LM, Stevanovic S, Weissbrich B, Yu Z, Restifo NP, Rosenberg SA, Trimble CL, Hinrichs CS JCI Insight. 2018 Apr 19;3(8). pii: 99488. doi: 10.1172/jci.insight.99488. PubMed Journal

---

Articles Citing HPV16 E7 TCR

Articles
Tumor cells fail to present MHC-II-restricted epitopes derived from oncogenes to CD4+ T cells. Brightman SE, Naradikian MS, Thota RR, Becker A, Montero L, Bahmanof M, Premlal ALR, Greenbaum JA, Peters B, Cohen EE, Miller AM, Schoenberger SP. JCI Insight. 2023 Jan 24;8(2):e165570. doi: 10.1172/jci.insight.165570. PubMed
Neoantigen-specific stem cell memory-like CD4(+) T cells mediate CD8(+) T cell-dependent immunotherapy of MHC class II-negative solid tumors. Brightman SE, Becker A, Thota RR, Naradikian MS, Chihab L, Zavala KS, Ramamoorthy Premlal AL, Griswold RQ, Dolina JS, Cohen EEW, Miller AM, Peters B, Schoenberger SP. Nat Immunol. 2023 Aug;24(8):1345-1357. doi: 10.1038/s41590-023-01543-9. Epub 2023 Jul 3. PubMed

If you have published an article using this material, please email us at to have your article added to this page.